Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Breast Cancer and Gastric Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT06328738
What this trial is testing

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2 Positive Solid Tumors+2 more
Enliven Therapeutics 275
Early research (Phase 1)Study completedNCT03841110
What this trial is testing

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsLymphomaGastric Cancer+15 more
Fate Therapeutics 37
Very early researchUnknownNCT05411432
What this trial is testing

Clinical Study of 68Ga Labeled HER2 Affibody Analogues

Who this might be right for
HER2-positive Breast Cancer and Gastric Cancer
Xijing Hospital 56
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Testing effectiveness (Phase 2)Active Not RecruitingNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 54
Testing effectiveness (Phase 2)Study completedNCT04276493
What this trial is testing

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Cancer
BeiGene 71
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Early research (Phase 1)Ended earlyNCT03680560
What this trial is testing

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Who this might be right for
Solid TumorHER-2 Protein Overexpression
Cogent Biosciences, Inc. 6
Early research (Phase 1)Study completedNCT00028535
What this trial is testing

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Who this might be right for
Male Breast CancerRecurrent Breast CancerRecurrent Endometrial Carcinoma+4 more
National Cancer Institute (NCI) 18
Early research (Phase 1)Study completedNCT03619681
What this trial is testing

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Who this might be right for
Breast CancerGastric Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 63
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Not applicableStudy completedNCT05955833
What this trial is testing

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study

Who this might be right for
Breast CancerMetastatic Breast CancerHER2-positive Breast Cancer+3 more
Amsterdam UMC, location VUmc 6
Testing effectiveness (Phase 2)Ended earlyNCT04467515
What this trial is testing

Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Who this might be right for
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Precirix 13
Early research (Phase 1)WithdrawnNCT06341647
What this trial is testing

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
GC Cell Corporation
Early research (Phase 1)Study completedNCT01148849
What this trial is testing

Safety Study of MGAH22 in HER2-positive Carcinomas

Who this might be right for
Breast CancerGastric Cancer
MacroGenics 66
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Early research (Phase 1)Study completedNCT01384253
What this trial is testing

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Who this might be right for
Breast NeoplasmsPeritoneal NeoplasmsOvarian Neoplasms+2 more
Orano Med LLC 18
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 383
Early research (Phase 1)Ended earlyNCT05514717
What this trial is testing

XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more
Day One Biopharmaceuticals, Inc. 57
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Next Page